Novo Nordisk A S
NONOF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000353278
No open-market purchases or sales by Novo Nordisk A S insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $5.36M in total; no superinvestor holds it.
Other share classesNVO
Q1 2026 vs. Q4 2025
How the institutions holding Novo Nordisk A S changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 2 | 3 | +1 |
| Shares | 5.28K | 90.3K | +85.1K (+1,611.6%) |
| Value | $269.4K | $13.9M | +$13.7M (+5,067.0%) |
New holders (2)
Institutions that held Novo Nordisk A S at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cygnus Capital Advisors, LLC | 54,800 | $12.7M | 8.65% |
| Generali Investments CEE, investicni spolecnost, a.s. | 30,319 | $1.08M | 0.06% |
Sold out (1)
Institutions that held Novo Nordisk A S at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Steigerwald, Gordon & Koch Inc. | 60 | $3.06K |